Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

NCT01231412

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +58 more
Locations
  • University of Colorado Denver, Colorado, United States
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01816971

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Dana Farber Boston, Massachusetts, United States
  • Washington University in St Louis St Louis, Missouri, United States
  • Sarah Cannon Cancer Center Nashville, Tennessee, United States
View Trial Details
Completed

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

NCT02719613

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 0020 Tucson, Arizona, United States
  • Local Institution - 0017 Bakersfield, California, United States
  • Local Institution - 0022 Fountain Valley, California, United States
  • Local Institution - 0016 West Hollywood, California, United States
View all 41 locations
View Trial Details
Completed

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

NCT02203643

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • IRCCS--CROB --CROB di Rionero in di Rionero in Vulture Rionero in Vulture, Italy
View Trial Details
Completed

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

NCT04557150

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Peter MacCallum Cancer Center Melbourne, Victoria, Australia
  • UZ Gent Ghent, Belgium
  • Rigshospitalet København Ø, Denmark
  • Odense Universitetshospital Odense C, Denmark
View all 20 locations
View Trial Details

Related conditions